News | April 29, 2015

Boston Scientific’s Eluvia Demonstrates 94.4 Percent Primary Patency Rate at Nine Months

Drug-eluting vascular stent system designed to treat peripheral artery disease through superficial femoral artery

Boston Scientific, Eluvia, MAJESTIC trial, vascular stent, PAD

April 29, 2015 — A key trial evaluating the Boston Scientific Eluvia drug-eluting vascular stent system met its primary endpoint, with more than 94 percent of the lesions treated for peripheral arterial disease (PAD) remaining open at nine months post implantation. This was accompanied by a target lesion revascularization rate (TLR) of less than four percent.

Results from the MAJESTIC trial were presented at the 37th Charing Cross International Symposium in London. The trial enrolled 57 patients across Europe, Australia and New Zealand with an average lesion length of 70.8 mm. 

"I have not seen clinical data this impressive for a vascular stent that has to perform in an environment as challenging as the superficial femoral artery," said Prof. Stefan Muller-Hulsbeck, M.D., Ph.D., principal investigator and chairman, Vascular Center Diako Flensburg and head of the Department of Diagnostic and Interventional Radiology/Neuroradiology, Academic Hospitals Flensburg, Germany. "Because of forces created by knee flexion, there is an increased risk of restenosis, but we are seeing little evidence of this in the MAJESTIC trial."

Nine-month data from the MAJESTIC trial demonstrated the following:

  • a primary patency rate of 94.4 percent;
  • a target lesion revascularization (TLR) rate of 3.6 percent; and
  • no deaths or amputations.

 

The Eluvia Stent System is the first stent purpose-built for the superficial femoral artery (SFA) that utilizes a polymer and paclitaxel combination designed to facilitate a sustained drug release to reduce restenosis. The system is built on the Innova Stent System platform consisting of a self-expanding nitinol stent with a paclitaxel-eluting biostable polymer matrix loaded on an advanced, low-profile delivery system. The innovative stent architecture, designed specifically for the SFA, features a closed-cell design at each end of the stent for more predictable deployment, and an open-cell design along the stent body for improved flexibility, strength and fracture resistance. A triaxial delivery system is designed for added support and placement accuracy.

The Eluvia Stent System is pending CE Mark and is not available for use or sale in the United States.

For more information: www.bostonscientific.com

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init